You need JavaScript to view this

Linac radiosurgery for high-grade gliomas: the University of Florida experience

Abstract

Purpose: Stereotactic radiosurgery has been reported as a promising boost technique for the treatment of selected patients with high-grade glioma. The first 11 patients given this treatment at the University of Florida are reported. Methods and Materials: Six patients with glioblastoma multiforme and five with anaplastic astrocytoma were carefully selected for treatment with linac radiosurgery. All patients had a Karnofsky performance status {>=} 90%. Median age of patients was 42.1 years. External-beam radiotherapy delivered a median dose of 60 Gy. Stereotactic radiosurgery was delivered to the enhancing tumor volume without margin. Median treatment volume was 14 cm{sup 3} (equivalent sphere diameter, 3 cm). The maximum volume of any tumor treated was 22.5 cm{sup 3} (equivalent sphere diameter, 3.5 cm). Median stereotactic radiosurgery boost dose was 12.5 Gy, and median prescription sphere was the 80% isodose shell. Results: Despite rigorous selection and aggressive stereotactic boost irradiation, this patient cohort had a median actuarial survival of 17 months. All patients have had progression of intracranial disease within 1 year of radiosurgery, and only 3 of 11 remain alive with a median follow-up of 13 months. Conclusion: These results differ significantly from others reported. Comparative analysis suggests tumor volume may be an important  More>>
Publication Date:
Apr 30, 1995
Product Type:
Journal Article
Resource Relation:
Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 32; Journal Issue: 1; Other Information: Copyright (c) 1995 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); PBD: 30 Apr 1995
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ASTROCYTOMAS; BRAIN; LINEAR ACCELERATORS; RADIOTHERAPY; SURGERY; SURVIVAL CURVES
OSTI ID:
20391111
Country of Origin:
United States
Language:
English
Other Identifying Numbers:
Journal ID: ISSN 0360-3016; IOBPD3; TRN: US03R1533057458
Submitting Site:
INIS
Size:
page(s) 205-210
Announcement Date:

Citation Formats

Buatti, John M, Friedman, William A, Bova, Frank J, and Mendenhall, William M. Linac radiosurgery for high-grade gliomas: the University of Florida experience. United States: N. p., 1995. Web. doi:10.1016/0360-3016(94)00498-A.
Buatti, John M, Friedman, William A, Bova, Frank J, & Mendenhall, William M. Linac radiosurgery for high-grade gliomas: the University of Florida experience. United States. doi:10.1016/0360-3016(94)00498-A.
Buatti, John M, Friedman, William A, Bova, Frank J, and Mendenhall, William M. 1995. "Linac radiosurgery for high-grade gliomas: the University of Florida experience." United States. doi:10.1016/0360-3016(94)00498-A. https://www.osti.gov/servlets/purl/10.1016/0360-3016(94)00498-A.
@misc{etde_20391111,
title = {Linac radiosurgery for high-grade gliomas: the University of Florida experience}
author = {Buatti, John M, Friedman, William A, Bova, Frank J, and Mendenhall, William M}
abstractNote = {Purpose: Stereotactic radiosurgery has been reported as a promising boost technique for the treatment of selected patients with high-grade glioma. The first 11 patients given this treatment at the University of Florida are reported. Methods and Materials: Six patients with glioblastoma multiforme and five with anaplastic astrocytoma were carefully selected for treatment with linac radiosurgery. All patients had a Karnofsky performance status {>=} 90%. Median age of patients was 42.1 years. External-beam radiotherapy delivered a median dose of 60 Gy. Stereotactic radiosurgery was delivered to the enhancing tumor volume without margin. Median treatment volume was 14 cm{sup 3} (equivalent sphere diameter, 3 cm). The maximum volume of any tumor treated was 22.5 cm{sup 3} (equivalent sphere diameter, 3.5 cm). Median stereotactic radiosurgery boost dose was 12.5 Gy, and median prescription sphere was the 80% isodose shell. Results: Despite rigorous selection and aggressive stereotactic boost irradiation, this patient cohort had a median actuarial survival of 17 months. All patients have had progression of intracranial disease within 1 year of radiosurgery, and only 3 of 11 remain alive with a median follow-up of 13 months. Conclusion: These results differ significantly from others reported. Comparative analysis suggests tumor volume may be an important prognostic factor in patients treated with stereotactic radiosurgery. Future studies need to define appropriate patient cohorts for the boost technique.}
doi = {10.1016/0360-3016(94)00498-A}
journal = {International Journal of Radiation Oncology, Biology and Physics}
issue = {1}
volume = {32}
journal type = {AC}
place = {United States}
year = {1995}
month = {Apr}
}